These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 6128757)

  • 21. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Morselli PL; Fournier V; Bossi L; Musch B
    Psychopharmacology Suppl; 1985; 2():128-36. PubMed ID: 2860656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metoclopramide and haloperidol in tardive dyskinesia.
    Bateman DN; Dutta DK; McClelland HA; Rawlins MD
    Br J Psychiatry; 1979 Dec; 135():505-8. PubMed ID: 43755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A therapeutic approach to tardive dyskinesia.
    Fahn S
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):19-24. PubMed ID: 2858474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluperlapine in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Gerlach J
    Psychopharmacology (Berl); 1984; 84(1):76-9. PubMed ID: 6149595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
    Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
    J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture?
    Mouret J; Khomais M; Lemoine P; Sebert P
    Eur Neurol; 1991; 31(4):199-203. PubMed ID: 1868860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained levodopa therapy in tardive dyskinesia.
    Hardie RJ; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1983 Jul; 46(7):685. PubMed ID: 6136552
    [No Abstract]   [Full Text] [Related]  

  • 30. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive dyskinesia: reversible and irreversible.
    Casey DE
    Psychopharmacology Suppl; 1985; 2():88-97. PubMed ID: 2860664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tardive dyskinesia: a review.
    Latimer PR
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S49-54. PubMed ID: 8564917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Switching antipsychotic treatment to aripiprazole in psychotic patients with neuroleptic-induced tardive dyskinesia: a 24-week follow-up study.
    Chan CH; Chan HY; Chen YC
    Int Clin Psychopharmacol; 2018 May; 33(3):155-162. PubMed ID: 29324468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug therapies for tardive dyskinesia: Part 1.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Jun; 49(6):13-6. PubMed ID: 21598866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
    Lockwood JT; Remington G
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose destyrosine-gamma-endorphin in tardive dyskinesia.
    Korsgaard S; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1982; 78(3):285-6. PubMed ID: 6130557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of tardive dyskinesia.
    Egan MF; Apud J; Wyatt RJ
    Schizophr Bull; 1997; 23(4):583-609. PubMed ID: 9365997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.